Novadoz Pharmaceuticals LLC (label), 2025-07: The dexrazoxane label states the drug is approved to reduce doxorubicin cardiomyopathy in metastatic breast cancer after 300 mg/m2 cumulative doxorubicin, and that initial U.S. approval was 1995.
Dexrazoxane for injection is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer
PDF p.1 (Highlights, Indications and Usage)
Novadoz Pharmaceuticals LLC (label), 2025-07: The dexrazoxane label states the drug is approved to reduce doxorubicin cardiomyopathy in metastatic breast cancer after 300 mg/m2 cumulative doxorubicin, and that initial U.S. approval was 1995. Regulatory text: no comparator of its own, but section 5.2 records the trial that limits its use – in patients given FAC with dexrazoxane from cycle 1, response rate was 48% vs 63% and time to progression was shorter than placebo, which is why the label forbids starting it with doxorubicin. Maker of this generic: Novadoz; originator Zinecard, Pfizer (see CHB-11). No funder/COI in a label. Study type: regulatory record.
